Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Apellis Pharmaceuticals Inc shares valued at $398,735 were sold by Francois Cedric on Jul 17 ’25. At $20.21 per share, Francois Cedric sold 19,725 shares. The insider’s holdings dropped to 331,605 shares worth approximately $6.66 million following the completion of this transaction.
Also, Watson David O. sold 5,000 shares, netting a total of over 97,750 in proceeds. Following the sale of shares at $19.55 each, the insider now holds 128,730 shares.
Before that, Francois Cedric had added 19,725 shares to its account. In a trade valued at $397,552, the Officer bought Apellis Pharmaceuticals Inc shares for $20.15 each.
As published in a research note from Raymond James on May 09, 2025, Apellis Pharmaceuticals Inc [APLS] has been rated down from a Strong buy to an Outperform and the price target has been revised to $52. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early May. As of April 29, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for APLS. Earlier on December 17, 2024, Goldman downgraded its rating. Their new recommendation was “a Neutral” for APLS stock which previously was a “a Buy”.
Analyzing APLS Stock Performance
On last trading session,, Apellis Pharmaceuticals Inc [NASDAQ: APLS] rose 0.95% to $20.09. The stock’s lowest price that day was $19.16, but it reached a high of $20.3199 in the same session. During the last five days, there has been a surge of approximately 0.25%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -45.78%. Shares of the company reached a 52-week high of $35.57 on 01/07/25 and a 52-week low of $16.10 on 05/15/25.
Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)
According to the 24-hour chart, there is a support level at 19.39, which, if violated, would cause prices to drop to 18.70. In the upper region, resistance lies at 20.55. The next price resistance is at 21.02. RSI (Relative Strength Index) is 60.00 on the 14-day chart, showing neutral technical sentiment.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp rise in short interest on 2025-06-30 jumping by 1.11 million shares to 26.15 million. Data from Yahoo Finance shows that the short interest on 2025-05-30 was 25.03 million shares. A jump of 4.26% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.18 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.18.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 76 in the next 12 months, up nearly 281.91% from the previous closing price of $19.9. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 113 by 2025, with the lowest price target being 39. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2025. On November 21, 2024, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and initiated coverage with a $31.
